Minkang Biotechnology is a national high-tech enterprise that concentrate on using biosensors technology to R&D, production and sale products for detecting chronic disease. It was registered and established in Beijing on June 8, 2010, and moved to Tianjin Binhai New Area in September, 2013. Since that, Minkang always focus on development of diabetes comprehensive offering with the enterprise tenet of “ Hand-in-hand to develop, dedicate Minkang to people ”.

MinKang Biotechnology Tianjin modern production base has a world-class 2000 square meters 100000 GMP purification workshop, 200 square meters laboratory and 1000 square meters professional R&D center. Minkang was successively identified as Tianjin Small and Medium-Size Technology Enterprise, Tianjin High-Tech Enterprise, National High-Tech Enterprise, Tianjin Key Product of Development; Get the support of the national fund repeatedly. It has pioneered to get ISO 13485 Quality Management System Certification and Europe Union CE Certification.

After more than ten years of development, Minkang has formed four leading domestic technical systems of electrochemistry, photochemistry, colloidal gold and immunofluorescence, and successfully utilizing single atom catalytic technology to effectively improve biosensing efficiency.

Series of blood glucose meters and matched test strips with the characteristics of “ accurate, simple and economy” are recognized by the mass consumers. Products contain detection of blood glucose, blood lipid, HbA1c, blood ketone, uric acid and multinomial diabetic index.

Minkang has always regarded technology as the basic platform for the company’s development. Since its establishment, MinKang has been strengthening its R&D investment. The chief scientist Mr. Cai Zongzhe is a doctor from a famous university in the United States. He has been engaged in diabetes monitoring technology for nearly 30 years. Meanwhile, the company also has about 10 R&D team members with master’s degree background. After years of R&D investment, MinKang has formed four leading technology system of electrochemistry, photochemistry, colloidal gold and immunity in China, and has obtained nearly 20 patents and software copyright.

Anhui Progression Biotechnology Co., Ltd., invested by Minkang Biology, has commenced construction in 2020. The project covers an area of nearly 7 acres. It will introduce 15 automatic production lines imported from Germany, build four major technology research and development centers, and become the largest professional industrial park in China's chronic disease detection technology industry.

Minkang has more than 180 agents throughout the country, covering more than 200 prefecture-level cities. OTC series products cover more than 200000 terminal pharmacies. And the series of hospital products are stationed in large, medium and small-size professional medical instructions more than thousands in China. While based on the domestic market, Minkang Biotechnology is also active expanding overseas markets. And keep close contacts with Southeast Asia, South Asia, Eastern Europe, Central Europe, Southern Europe, West Africa, North America and other regions.